A REtrospective Non-interventional Study to Assess the Effectiveness of AfLibercept in Patients With Myopic CNV
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Myopia
- Focus Therapeutic Use
- Acronyms REALM
- Sponsors Bayer
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 19 Oct 2022 Planned End Date changed from 7 Oct 2022 to 27 Oct 2022.
- 19 Oct 2022 Planned primary completion date changed from 7 Oct 2022 to 27 Oct 2022.